Professor Eric W Alton

Publications


Journals

  • Griesenbach U; Alton EW. (10 Jan 2012). Progress in Gene and Cell Therapy for Cystic Fibrosis Lung Disease. Curr Pharm Des.
  • Nair CG; Shoemark A; Donovan S; Hogg C; Alton EW; Williams HD; Davies JC. (2011). POISON IN THE LUNG - CYANIDE, AT CONCENTRATIONS FOUND IN THE SPUTUM OF PSEUDOMONAS AERUGINOSA INFECTED CF PATIENTS INHIBITS THE BEATING OF HUMAN RESPIRATORY CILIA IN VITRO. PEDIATR PULM. 319-319.
  • Griesenbach U; McLachlan G; Collie D; Innes J; Higgins T; Cheng S; Scheule R; Alton EW; et alDavies JC; Hyde SC; Porteous D; Boyd AC; UK CF Gene Therapy Consortium. (2011). TOXICOLOGY STUDIES IN SUPPORT OF THE UK CF GENE THERAPY CONSORTIUM'S MULTI-DOSE CLINICAL TRIAL. PEDIATR PULM. 298-298.
  • Davies JC; Davies G; Gill D; Hyde S; Boyd C; Innes JA; Porteous D; Cheng S; et alScheule R; Higgins T; Griesenbach U; Alton EW. (2011). SAFETY AND EXPRESSION OF A SINGLE DOSE OF LIPID-MEDIATED CFTR GENE THERAPY TO THE UPPER AND LOWER AIRWAYS OF PATIENTS WITH CF. PEDIATR PULM. 281-281.
  • Hyde SC; Sumner-Jones SG; Pringle IA; Cheng SH; Scheule RK; Alton EW; Davies JC; Higgins T; et alBoyd A; Innes J; Porteous DJ; Gill DR; Griesenbach U. (2011). MULTIPLE DOSES OF LIPID-MEDIATED GENE THERAPY NEBULISED TO THE MOUSE LUNG SHOW ROBUST AND SUSTAINED CFTR EXPRESSION. PEDIATR PULM. 281-281.
  • McLachlan G; Davidson H; Holder E; Davies LA; Pringle IA; Sumner-Jones SG; Baker A; Tennant P; et alGordon C; Vrettou C; Blundell R; Hyndman L; Stevenson B; Wilson A; Doherty A; Shaw DJ; Coles RL; Painter H; Cheng SH; Scheule RK; Davies JC; Innes JA; Hyde SC; Griesenbach U; Alton EW; Boyd AC; Porteous DJ; Gill DR; Collie DD. (Oct 2011). Pre-clinical evaluation of three non-viral gene transfer agents for cystic fibrosis after aerosol delivery to the ovine lung. Gene Ther. 18:996-1005. DOI.
  • Alexander BL; Ali RR; Alton EWFW; Bainbridge JW; Braun S; Cheng SH; Flotte TR; Gaspar HB; et alGrez M; Griesenbach U; Kaplitt MG; Ott MG; Seger R; Simons M; Thrasher AJ; Thrasher AZ; Herttuala SY. (Dec 2007). Progress and prospects: gene therapy clinical trials (part 1) (vol 14, pg 1439, 2007). GENE THER. 14:1754-1754. DOI.
  • Hyde SC; Pringle IA; Abdullah S; Lawton AE; Davies LA; Varathalingam A; Nunez-Alonso G; Green AM; et alBazzani RP; Sumner-Jones SG; Chan M; Li H; Yew NS; Cheng SH; Boyd AC; Davies JC; Griesenbach U; Porteous DJ; Sheppard DN; Munkonge FM; Alton EWFW; Gill DR. (May 2008). CpG-free plasmids confer reduced inflammation and sustained pulmonary gene expression. NAT BIOTECHNOL. 26:549-551. DOI.
  • Griesenbach U; Alton EWFW. (Jan 2009). Cystic fibrosis Ferreting with fibroblasts for cystic fibrosis. GENE THER. 16:1-2. DOI.
  • Miller AM; Munkonge FM; Alton EW; Dean DA. (Nov 2009). Identification of protein cofactors necessary for sequence-specific plasmid DNA nuclear import. Mol Ther. 17:1897-1903. DOI.
  • Ogilvie V; Passmore M; Hyndman L; Jones L; Stevenson B; Wilson A; Davidson H; Kitchen RR; et alGray RD; Shah P; Alton EW; Davies JC; Porteous DJ; Boyd AC. (Nov 2011). Differential global gene expression in cystic fibrosis nasal and bronchial epithelium. Genomics. 98:327-336. DOI.
  • Ban H; Inoue M; Griesenbach U; Munkonge F; Chan M; Iida A; Alton E; Hasegawa M. (Dec 2007). Expression and maturation of Sendai virus vector-derived CFTR protein: functional and biochemical evidence using a GFP-CFTR fusion protein. GENE THER. 14:1688-1694. DOI.
  • Davies J; Voase N; Dewar M; Mullard K; Gammie F; Saunders C; Horsley A; Gray R; et alMacLeod K; Somerton L; Higgins T; Donovan T; Cornish N; Hansell D; Aziz Z; Ashby D; Geddes D; Greening A; Cunningham S; Innes A; Alton E. (2007). UKCF Gene Therapy Consortium tracking study: Response of clinically-available assays to intravenous antibiotics. PEDIATR PULM. 347-347.
  • Macleod K; Horsley A; Gray R; Imrie M; Leiton J; Dewar M; Voase N; Saunders C; et alHyde S; Gill D; Geddes D; Davies JC; Alton E; Porteous D; Boyd C; Cunningham S; Innes JA; Greening A. (2007). UK cystic fibrosis gene therapy consortium tracking study: Exhaled breath condensate pH increases with treatment of an infective exacerbation. PEDIATR PULM. 343-344.
  • Gray RD; Horsley A; Macleod K; Imrie M; Dewar M; Voase N; Donovan J; Hyde S; et alGill D; Griesenbach U; Davies JC; Alton E; Boyd AC; Porteous D; Cunningham S; Innes JA; Greening AP. (2007). UKCF gene therapy consortium tracking study: Sputum and serum calprotectin are useful novel measurements in CF exacerbation. PEDIATR PULM. 338-338.
  • Horsley A; Macleod K; Saunders C; Gray RD; Dewar M; Voase N; Porteous D; Boyd C; et alHyde S; Gill D; Geddes D; Greening AP; Cunningham S; Davies JC; Alton E; Innes JA. (2007). UKCF gene therapy consortium tracking study: Lung clearance index improves with treatment of an infective exacerbation. PEDIATR PULM. 335-336.
  • Rakonczay Z; Hegyi P; Hasegawa M; Inoue M; You J; Iida A; Ignath I; Alton EWFW; et alGriesenbach U; Ovari G; Vag J; Da Paula AC; Crawford RM; Varga G; Amaral MD; Mehta A; Lonovics J; Argent BE; Gray MA. (Feb 2008). CFTR gene transfer to human cystic fibrosis pancreatic duct cells using a sendai virus vector. J CELL PHYSIOL. 214:442-455. DOI.
  • Horsley AR; Gustafsson PM; Macleod KA; Saunders C; Greening AP; Porteous DJ; Davies JC; Cunningham S; et alAlton EWFW; Innes JA. (Feb 2008). Lung clearance index is a sensitive, repeatable and practical measure of airways disease in adults with cystic fibrosis. THORAX. 63:135-140. DOI.
  • Davies JC; Cunningham S; Alton EWFW; Innes JA. (Feb 2008). Lung clearance index in CF: a sensitive marker of lung disease severity. THORAX. 63:96-97. DOI.
  • Davies LA; McLachlan G; Sumner-Jones SG; Ferguson D; Baker A; Tennant P; Gordon C; Vrettou C; et alBaker E; Zhu J; Alton EWFW; Collie DDS; Porteous DJ; Hyde SC; Gill DR. (Jul 2008). Enhanced lung gene expression after aerosol delivery of concentrated pDNA/PEI complexes. MOL THER. 16:1283-1290. DOI.
  • McBain SC; Griesenbach U; Xenariou S; Keramane A; Batich CD; Alton EWFW; Dobson J. (8 Oct 2008). Magnetic nanoparticles as gene delivery agents: enhanced transfection in the presence of oscillating magnet arrays. NANOTECHNOLOGY. 19. DOI.
  • MacGregor G; Gray RD; Hilliard TN; Imrie M; Boyd AC; Alton EWFW; Bush A; Davies JC; et alInnes JA; Porteous DJ; Greening AP. (Sep 2008). Biomarkers for cystic fibrosis lung disease: Application of SELDI-TOF mass spectrometry to BAL fluid. J CYST FIBROS. 7:352-358. DOI.
  • Davidson H; Wilson A; Gray RD; Horsley A; Pringle IA; McLachlan G; Nairn AC; Stearns C; et alGibson J; Holder E; Jones L; Doherty A; Coles R; Sumner-Jones SG; Wasowicz M; Manvell M; Griesenbach U; Hyde SC; Gill DR; Davies J; Collie DDS; Alton EWFW; Porteous DJ; Boyd AC. (Dec 2009). An immunocytochemical assay to detect human CFTR expression following gene transfer. MOL CELL PROBE. 23:272-280. DOI.
  • Tan H; Regamey N; Hilliard T; Alton E; Bush A; Lloyd CM; Davies J. (2009). EXPLORING THE PHENOTYPE OF THE LYMPHOCYTIC INFILTRATE IN THE CF AIRWAY: DO IL17+CELLS PLAY A ROLE IN DISEASE PATHOGENESIS?. PEDIATR PULM. 254-254.
  • Holder E; Stevenson B; Farley R; Hilliard T; Wodehouse T; Somerton L; Larsen M; O'Donoghue J; et alColes RL; Scheule RK; Cheng SH; Gill DR; Hyde SC; Griesenbach U; Alton EWFW; Porteous DJ; Boyd AC. (Jan 2010). Detection of CFTR transgene mRNA expression in respiratory epithelium isolated from the murine nasal cavity. J GENE MED. 12:55-63. DOI.
  • Mitomo K; Griesenbach U; Inoue M; Somerton L; Meng C; Akiba E; Tabata T; Ueda Y; et alFrankel GM; Farley R; Singh C; Chan M; Munkonge F; Brum A; Xenariou S; Escudero-Garcia S; Hasegawa M; Alton EW. (Jun 2010). Toward gene therapy for cystic fibrosis using a lentivirus pseudotyped with Sendai virus envelopes. Mol Ther. 18:1173-1182. DOI.
  • Regamey N; Tsartsali L; Hilliard TN; Fuchs O; Tan HL; Zhu J; Qiu YS; Alton EW; et alJeffery PK; Bush A; Davies JC. (Feb 2012). Distinct patterns of inflammation in the airway lumen and bronchial mucosa of children with cystic fibrosis. Thorax. 67:170-176. DOI.
  • Davies JC; Alton EW. (2011). Design of gene therapy trials in CF patients. Methods Mol Biol. 741:55-68. DOI.
  • Griesenbach U; Alton EW. (1 Apr 2011). Current status and future directions of gene and cell therapy for cystic fibrosis. BioDrugs. 25:77-88. DOI.
  • Ives A; Irving S; Hogg C; Edey A; Hansell D; Alton EW; Davies JC; Bush A. (2010). LUNG CLEARANCE INDEX AND STRUCTURAL LUNG DISEASE IN CYSTIC FIBROSIS: A COMPARISON WITH PRIMARY CILIARY DYSKINESIA. PEDIATR PULM. 361-362.
  • Singh C; Munkonge F; Smith S; Griesenbach U; Carzaniga R; Pape T; Cheng S; Rogers A; et alDewar A; Alton EW. (2010). QUANTITATIVE BIOLOGICAL IMAGING OF PLASMID DNA IN LIVE HUMAN AIRWAY EPITHELIAL CELLS FOLLOWING NON-VIRAL GENE TRANSFER. PEDIATR PULM. 313-313.
  • Griesenbach U; Wilson KM; Farley R; Meng C; Scheule RK; Cheng SH; Alton EW. (2010). ASSESSMENT OF THE NUCLEAR PORE DILATING AGENT TCHD IN DIFFERENTIATED AIRWAY EPITHELIUM. PEDIATR PULM. 304-305.
  • Griesenbach U; Inoue M; Meng C; Brum AM; Farley R; Newman N; Akiba E; Hasegawa M; et alAlton EW. (2010). SIV VECTOR PSEUDOTYPED WITH SEV-F/HN ENVELOPE PROTEINS PRODUCES LONG LASTING EXPRESSION IN THE MURINE LUNG, IS READMINISTRABLE & TRANSFECTS HUMAN AIRWAY MODELS. PEDIATR PULM. 304-304.
  • Alton EW; Boyd C; Cunningham S; Davies JC; Hyde SC; Innes JA; Gill DR; Greening A; et alGriesenbach U; Higgins T; Porteous DJ; UK CF Gene Therapy Consortium. (2010). LONGITUDINAL ASSESSMENT OF BIOMARKERS FOR CLINICAL TRIALS OF NOVEL THERAPEUTIC AGENTS; THE RUN-IN STUDY. PEDIATR PULM. 298-298.
  • Naderi K; Donovan J; Leaver N; Brown S; Tan H; Alton EW; Bush A; Davies JC. (2010). VITAMIN D-DEFICIENT CF CHILDREN HAVE REDUCED LEVELS OF ANTIMICROBIAL DEFENCE MOLECULES IN THE AIRWAYS. PEDIATR PULM. 279-279.
  • Donovan J; Ives A; Hogg C; Bush A; Alton EW; Davies JC. (2010). COMPARISON OF LOCAL & SYSTEMIC INFLAMMATORY RESPONSE IN PATIENTS WITH CYSTIC FIBROSIS & PRIMARY CILIARY DYSKINESIA. PEDIATR PULM. 266-266.
  • Kernan NG; Cullinan P; Alton EW; Bilton D; Griesenbach U. (2010). ORAL CONTRACEPTIVE USE DOES NOT AFFECT CF DISEASE SEVERITY. PEDIATR PULM. 250-250.
  • Griesenbach U; Vicente CC; Roberts MJ; Meng C; Soussi S; Xenariou S; Tennant P; Baker A; et alBaker E; Gordon C; Vrettou C; McCormick D; Coles R; Green AM; Lawton AE; Sumner-Jones SG; Cheng SH; Scheule RK; Hyde SC; Gill DR; Collie DD; McLachlan G; Alton EW. (Apr 2011). Secreted Gaussia luciferase as a sensitive reporter gene for in vivo and ex vivo studies of airway gene transfer. Biomaterials. 32:2614-2624. DOI.
  • Lyne JC; Green AC; Alton EW; Clague JR. (Mar 2011). Stem cell infusion into the vein of Marshall. Europace. 13:438. DOI.
  • Davies JC; Alton EW. (Nov 2010). Gene therapy for cystic fibrosis. Proc Am Thorac Soc. 7:408-414. DOI.
  • Griesenbach U; McLachlan G; Owaki T; Somerton L; Shu T; Baker A; Tennant P; Gordon C; et alVrettou C; Baker E; Collie DD; Hasegawa M; Alton EW. (Feb 2011). Validation of recombinant Sendai virus in a non-natural host model. Gene Ther. 18:182-188. DOI.
  • Regamey N; Jeffery PK; Alton EW; Bush A; Davies JC. (Jul 2011). Airway remodelling and its relationship to inflammation in cystic fibrosis. Thorax. 66:624-629. DOI.
  • Simmonds NJ; D'Souza L; Roughton M; Alton EW; Davies JC; Hodson ME. (May 2011). Cystic fibrosis and survival to 40 years: a study of cystic fibrosis transmembrane conductance regulator function. Eur Respir J. 37:1076-1082. DOI.
  • Griesenbach U; Alton EW. (Aug 2009). Cystic fibrosis gene therapy: successes, failures and hopes for the future. Expert Rev Respir Med. 3:363-371. DOI.
  • Griesenbach U; Soussi S; Larsen MB; Casamayor I; Dewar A; Regamey N; Bush A; Shah PL; et alDavies JC; Alton EW. (Mar 2011). Quantification of periciliary fluid height in human airway biopsies is feasible, but not suitable as a biomarker. Am J Respir Cell Mol Biol. 44:309-315. DOI.
  • Xenariou S; Liang HD; Griesenbach U; Zhu J; Farley R; Somerton L; Singh C; Jeffery PK; et alScheule RK; Cheng SH; Geddes DM; Blomley M; Alton EW. (Jan 2010). Low-frequency ultrasound increases non-viral gene transfer to the mouse lung. Acta Biochim Biophys Sin (Shanghai). 42:45-51.
  • Donovan J; Davies JC; Alton EW. (2009). OPTIMISING SPUTUM PROCESSING FOR ANALYSIS OF INFLAMMATORY MARKERS IN CF: REMOVAL OF DITHIOTHREITOL BY DIALYSIS DOES NOT IMPROVE DETECTION OF CYTOKINES. PEDIATR PULM. 357-357.
  • Voase NW; Davies G; Reid PA; Macleod KA; Dewar MH; Bell NJ; Saunders C; Greening AP; et alCunningham S; Innes JA; Alton EW; Davies JC. (2009). SUCCESS AND UTILITY OF SPUTUM INDUCTION IN NON-EXPECTORATING CF SUBJECTS: DATA FROM THE UK CF GENE THERAPY RUN-IN STUDY. PEDIATR PULM. 337-338.
  • Davies JC; MacLean F; Nilsson E; Kollberg H; Alton EW. (2009). INCREASED ADHERENCE OF P. AERUGINOSA TO BUCCAL EPITHELIAL CELLS IN THE PRESENCE OF SPECIFIC ANTI-PSEUDOMONAS IGY. PEDIATR PULM. 337-337.
  • Sumner-Jones S; McCormick D; Coles R; Pringle IA; McLachlan G; Collie DD; Vrettou C; Davies JC; et alAlton EW; Gill DR; Hyde SC. (2009). OPTIMISATION OF MOLECULAR ASSAYS FOR CLINICAL TRIAL OF GL67A/PDNA DELIVERY TO NOSE AND LUNG OF CF PATIENTS. PEDIATR PULM. 306-306.
  • Davies JC; Gill D; Griesenbach U; Voase N; Davies G; Higgins T; Innes JA; Boyd C; et alPorteous D; Hyde S; Alton EW. (2009). EVALUATION OF SAFETY AND GENE EXPRESSION WITH A SINGLE DOSE OF PGM169/GL67A ADMINISTERED TO THE NOSE AND LUNG OF INDIVIDUALS WITH CF: THE UK CF GENE THERAPY CONSORTIUM "PILOT STUDY". PEDIATR PULM. 305-306.
  • Griesenbach U; Meng C; Farley R; Wasowicz MY; Munkonge FM; Chan M; Stoneham C; Sumner-Jones SG; et alPringle IA; Gill DR; Hyde SC; Stevenson B; Holder E; Ban H; Hasegawa M; Cheng SH; Scheule RK; Sinn PL; McCray PB; Alton EW. (Mar 2010). The use of carboxymethylcellulose gel to increase non-viral gene transfer in mouse airways. Biomaterials. 31:2665-2672. DOI.
  • Griesenbach U; Sumner-Jones SG; Holder E; Munkonge FM; Wodehouse T; Smith SN; Wasowicz MY; Pringle I; et alCasamayor I; Chan M; Coles R; Cornish N; Dewar A; Doherty A; Farley R; Green AM; Jones BL; Larsen MD; Lawton AE; Manvell M; Painter H; Singh C; Somerton L; Stevenson B; Varathalingam A; Siegel C; Scheule RK; Cheng SH; Davies JC; Porteous DJ; Gill DR; Boyd AC; Hyde SC; Alton EW. (Jul 2010). Limitations of the murine nose in the development of nonviral airway gene transfer. Am J Respir Cell Mol Biol. 43:46-54. DOI.
  • Munkonge FM; Amin V; Hyde SC; Green AM; Pringle IA; Gill DR; Smith JW; Hooley RP; et alXenariou S; Ward MA; Leeds N; Leung KY; Chan M; Hillery E; Geddes DM; Griesenbach U; Postel EH; Dean DA; Dunn MJ; Alton EW. (25 Sep 2009). Identification and functional characterization of cytoplasmic determinants of plasmid DNA nuclear import. J Biol Chem. 284:26978-26987. DOI.
  • Davies JC; Alton EW. (May 2009). Monitoring respiratory disease severity in cystic fibrosis. Respir Care. 54:606-617.
  • Fidler KJ; Hilliard TN; Bush A; Johnson M; Geddes DM; Turner MW; Alton EW; Klein NJ; et alDavies JC. (Feb 2009). Mannose-binding lectin is present in the infected airway: a possible pulmonary defence mechanism. Thorax. 64:150-155. DOI.
  • Griesenbach U; Alton EW; UK Cystic Fibrosis Gene Therapy Consortium. (27 Feb 2009). Gene transfer to the lung: lessons learned from more than 2 decades of CF gene therapy. Adv Drug Deliv Rev. 61:128-139. DOI.
  • Griesenbach U; Meng C; Farley R; Gardner A; Brake MA; Frankel GM; Gruenert DC; Cheng SH; et alScheule RK; Alton EW. (Apr 2009). The role of doxorubicin in non-viral gene transfer in the lung. Biomaterials. 30:1971-1977. DOI.
  • Griesenbach U; Munkonge FM; Sumner-Jones S; Holder E; Smith SN; Boyd AC; Gill DR; Hyde SC; et alPorteous D; Alton EW; UK Cystic Fibrosis Gene Therapy Consortium. (2008). Assessment of CFTR function after gene transfer in vitro and in vivo. Methods Mol Biol. 433:229-242. DOI.
  • Davies LA; Varathalingam A; Painter H; Lawton AE; Sumner-Jones SG; Nunez-Alonso GA; Chan M; Munkonge F; et alAlton EW; Hyde SC; Gill DR. (May 2008). Adenovirus-mediated in utero expression of CFTR does not improve survival of CFTR knockout mice. MOL THER. 16:812-818. DOI.
  • Griesenbach U; Smith SN; Farley R; Singh C; Alton EW. (Oct 2008). Validation of nasal potential difference measurements in gut-corrected CF knockout mice. Am J Respir Cell Mol Biol. 39:490-496. DOI.
  • Larsen MD; Griesenbach U; Goussard S; Gruenert DC; Geddes DM; Scheule RK; Cheng SH; Courvalin P; et alGrillot-Courvalin C; Alton EW. (Mar 2008). Bactofection of lung epithelial cells in vitro and in vivo using a genetically modified Escherichia coli. Gene Ther. 15:434-442. DOI.
  • Hilliard TN; Zhu J; Farley R; Escudero-Garcia S; Wainwright BJ; Jeffery PK; Griesenbach U; Bush A; et alDavies JC; Alton EW. (Jul 2008). Nasal abnormalities in cystic fibrosis mice independent of infection and inflammation. Am J Respir Cell Mol Biol. 39:19-25. DOI.
  • Regamey N; Ochs M; Hilliard TN; Muehlfeld C; Cornish N; Fleming L; Saglani S; Alton EW; et alBush A; Jeffery P; Davies JC. (2007). Airway smooth muscle remodeling in children with cystic fibrosis. PEDIATR PULM. 349-350.
  • Mitomo K; Griesenbach U; Inoue M; Washizawa K; Fujikawa S; Iwasaki H; Somerton L; Farley R; et alSingh C; Hasegawa M; Alton EW. (2007). Potential airway stem/progenitor cell integration after transduction with a lentiviral vector pseudotyped with sendai virus envelope proteins. PEDIATR PULM. 286-286.
  • Reizarney N; Tsartsali L; Hilliard TN; Cornish N; Zhu J; Jeffery PK; Alton EW; Bush A; et alDavies JC. (2007). Airway mucosa inflammation in children with cystic fibrosis. PEDIATR PULM. 262-263.
  • Griesenbach U; Jeswiet SB; Larsen MD; Bakar Y; Voase NW; Gammie F; Gray RD; Horsley A; et alImrie M; Dewar M; Marriott C; Geddes DM; Davies JC; Alton EW. (2007). UKCF gene therapy consortium tracking study: Change in sputum properties in response to IV antibiotic. PEDIATR PULM. 229-229.
  • Regamey N; Ochs M; Hilliard TN; Mühlfeld C; Cornish N; Fleming L; Saglani S; Alton EW; et alBush A; Jeffery PK; Davies JC. (15 Apr 2008). Increased airway smooth muscle mass in children with asthma, cystic fibrosis, and non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med. 177:837-843. DOI.
  • Regamey N; Hilliard TN; Saglani S; Zhu J; Balfour-Lynn IM; Rosenthal M; Jeffery PK; Alton EW; et alBush A; Davies JC. (Jan 2008). Endobronchial biopsy in childhood. Chest. 133:312. DOI.
  • Griesenbach U; Meng C; Farley R; Cheng SH; Scheule RK; Davies MH; Wolstenholme-Hogg PC; ten Hove W; et alvan der Hoeven P; Sinn PL; McCray PB; Inoue M; Geddes DM; Hasegawa M; Frankel G; Wiles S; Alton EW. (Apr 2008). In vivo imaging of gene transfer to the respiratory tract. Biomaterials. 29:1533-1540. DOI.
  • Davies JC; Alton EW; Bush A. (15 Dec 2007). Cystic fibrosis. BMJ. 335:1255-1259. DOI.
  • Davies JC; Griesenbach U; Alton EW. (May 2005). Modifier genes in cystic fibrosis. Pediatric Pulmonolgy.
  • Davies JC; Alton E; Griesenbach U. (2005). Cystic fibrosis modifier genes. Journal of the Royal Society of Medicine. supplement 45, 98:47-54.
  • Davies JC; Turner MW; Klein N; MBL CF Study Group. (2004). Impaired pulmonary status in cystic fibrosis adults with two mutated MBL-2 alleles. European Respiratory Journal. 24:708-804.
  • Hollax EJ; Davies J; Griesenbach U; Burgess J; Alton EW; Armour JA. (Dec 2005). Beta-defensin genomic copy number is not a modifier locus for cystic fibrosis. J Negat Results Biomed. 4, 7.
  • L Stewart; M Manvell; E Hillery; CJ Etheridge; RG Cooper; H Stark; M van Heel; M Preuss; et alAlton EWFW; AD Miller. (2001). Physico-chemical analysis of cationic liposome-DNA complexes (lipoplexes) with respect to in vitro and in vivo gene delivery efficacy. J Chem Soc. 2:624-632.
  • Ferrari S; Griesenbach U; Geddes DM; Alton EW. (2003). Immunological hurdles to lung gene therapy. Clinical and Experimental Immunology. 132:1-8.
  • Ferrari S; Griesenbach U; Iida A; Farley R; Wright AM; Zhu J; Munkonge FM; Smith SN; et alYou J; Ban H; Inoue M; Chan M; Singh C; Verdon B; Argent BE; Wainwright B; Jeffery PK; Geddes DM; Porteous DJ; Hyde SC; Gray MA; Hasegawa M; Alton EW. (Oct 2007). Sendai virus-mediated CFTR gene transfer to the airway epithelium. Gene Ther. 14:1371-1379. DOI.
  • Hilliard TN; Regamey N; Shute JK; Nicholson AG; Alton EW; Bush A; Davies JC. (Dec 2007). Airway remodelling in children with cystic fibrosis. Thorax. 62:1074-1080. DOI.
  • Regamey N; Hilliard TN; Saglani S; Zhu J; Scallan M; Balfour-Lynn IM; Rosenthal M; Jeffery PK; et alAlton EW; Bush A; Davies JC. (Jun 2007). Quality, size, and composition of pediatric endobronchial biopsies in cystic fibrosis. Chest. 131:1710-1717. DOI.
  • Xenariou S; Griesenbach U; Liang HD; Zhu J; Farley R; Somerton L; Singh C; Jeffery PK; et alFerrari S; Scheule RK; Cheng SH; Geddes DM; Blomley M; Alton EW. (May 2007). Use of ultrasound to enhance nonviral lung gene transfer in vivo. Gene Ther. 14:768-774. DOI.
  • Aziz ZA; Davies JC; Alton EW; Wells AU; Geddes DM; Hansell DM. (Feb 2007). Computed tomography and cystic fibrosis: promises and problems. Thorax. 62:181-186. DOI.
  • Tagawa T; Manvell M; Brown N; Keller M; Perouzel E; Murray KD; Harbottle RP; Tecle M; et alBooy F; Brahimi-Horn MC; Coutelle C; Lemoine NR; Alton EW; Miller AD. (May 2002). Characterisation of LMD virus-like nanoparticles self-assembled from cationic liposomes, adenovirus core peptide mu and plasmid DNA. Gene Ther. 9:564-576. DOI.
  • Radke PW; Heinl-Green A; Frass OM; Post MJ; Sato K; Geddes DM; Alton EW. (Jan 2006). Evaluation of the porcine ameroid constrictor model of myocardial ischemia for therapeutic angiogenesis studies. Endothelium. 13:25-33. DOI.
  • Griesenbach U; Geddes DM; Alton EW. (Jul 2006). Gene therapy progress and prospects: cystic fibrosis. Gene Ther. 13:1061-1067. DOI.
  • Holder E; Griesenbach U; Li S; Huang L; Rogers DF; Jeffery PK; Geddes DM; Alton EW. (Dec 2006). Intravenously administered oligonucleotides can be delivered to conducting airway epithelium via the bronchial circulation. Gene Ther. 13:1628-1638. DOI.
  • Xenariou S; Griesenbach U; Ferrari S; Dean P; Scheule RK; Cheng SH; Geddes DM; Plank C; et alAlton EW. (Nov 2006). Using magnetic forces to enhance non-viral gene transfer to airway epithelium in vivo. Gene Ther. 13:1545-1552. DOI.
  • Hillery E; Munkonge FM; Xenariou S; Dean DA; Alton EW. (15 May 2006). Nondisruptive, sequence-specific coupling of fluorochromes to plasmid DNA. Anal Biochem. 352:169-175. DOI.
  • Griesenbach U; Kitson C; Escudero Garcia S; Farley R; Singh C; Somerton L; Painter H; Smith RL; et alGill DR; Hyde SC; Chow YH; Hu J; Gray M; Edbrooke M; Ogilvie V; MacGregor G; Scheule RK; Cheng SH; Caplen NJ; Alton EW. (2006). Inefficient cationic lipid-mediated siRNA and antisense oligonucleotide transfer to airway epithelial cells in vivo. Respir Res. 7:26. DOI.
  • Emerson M; Renwick L; Tate S; Rhind S; Milne E; Painter H; Boyd AC; McLachlan G; et alGriesenbach U; Cheng SH; Gill DR; Hyde SC; Baker A; Alton EW; Porteous DJ; Collie DDS. (Oct 2003). Transfection efficiency and toxicity following delivery of naked plasmid DNA and cationic lipid-DNA complexes to ovine lung segments. MOL THER. 8:646-653. DOI.
  • Middleton PG; Pollard KA; Donohoo E; Wheatley JR; Geddes DM; Alton EW. (15 Nov 2003). Airway surface liquid calcium modulates chloride permeability in the cystic fibrosis airway. AM J RESP CRIT CARE. 168:1223-1226. DOI.
  • Griesenbach U; Boyton RJ; Somerton L; Garcia SE; Ferrari S; Owaki T; Ya-Fen Z; Geddes DM; et alHasegawa M; Altmann DM; Alton EW. (Mar 2006). Effect of tolerance induction to immunodominant T-cell epitopes of Sendai virus on gene expression following repeat administration to lung. Gene Ther. 13:449-456. DOI.
  • Equi AC; Davies JC; Painter H; Hyde S; Bush A; Geddes DM; Alton EW. (Apr 2006). Exploring the mechanisms of macrolides in cystic fibrosis. Respir Med. 100:687-697. DOI.
  • Griesenbach U; Inoue M; Hasegawa M; Alton EW. (Aug 2005). Sendai virus for gene therapy and vaccination. Curr Opin Mol Ther. 7:346-352.
  • Heinl-Green A; Radke PW; Munkonge FM; Frass O; Zhu J; Vincent K; Geddes DM; Alton EW. (Jul 2005). The efficacy of a 'master switch gene' HIF-1alpha in a porcine model of chronic myocardial ischaemia. Eur Heart J. 26:1327-1332. DOI.
  • Ulrich K; Stern M; Goddard ME; Williams J; Zhu J; Dewar A; Painter HA; Jeffery PK; et alGill DR; Hyde SC; Geddes DM; Takata M; Alton EW. (Jun 2005). Keratinocyte growth factor therapy in murine oleic acid-induced acute lung injury. Am J Physiol Lung Cell Mol Physiol. 288:L1179-L1192. DOI.
  • Radke PW; Griesenbach U; Kivela A; Vick T; Judd D; Munkonge F; Willis S; Geddes DM; et alYla-Herttuala S; Alton EW. (Jun 2005). Vascular oligonucleotide transfer facilitated by a polymer-coated stent. Hum Gene Ther. 16:734-740. DOI.
  • Davies JC; Davies M; McShane D; Smith S; Chadwick S; Jaffe A; Farley R; Collins L; et alBush A; Scallon M; Pepper J; Geddes DM; Alton EW. (1 May 2005). Potential difference measurements in the lower airway of children with and without cystic fibrosis. Am J Respir Crit Care Med. 171:1015-1019. DOI.
  • Davies MG; Geddes DM; Alton EW. (1 Apr 2005). The effect of varying tonicity on nasal epithelial ion transport in cystic fibrosis. Am J Respir Crit Care Med. 171:760-763. DOI.
  • Davies JC; Alton EW. (2005). Airway gene therapy. Adv Genet. 54:291-314. DOI.
  • Ferrari S; Griesenbach U; Shiraki-Iida T; Shu T; Hironaka T; Hou X; Williams J; Zhu J; et alJeffery PK; Geddes DM; Hasegawa M; Alton EW. (Nov 2004). A defective nontransmissible recombinant Sendai virus mediates efficient gene transfer to airway epithelium in vivo. Gene Ther. 11:1659-1664. DOI.
  • Griesenbach U; Geddes DM; Alton EW. (Nov 2004). Advances in cystic fibrosis gene therapy. Curr Opin Pulm Med. 10:542-546.
  • Griesenbach U; Geddes DM; Alton EW. (Oct 2004). Gene therapy for cystic fibrosis: an example for lung gene therapy. Gene Ther. 11 Suppl 1:S43-S50. DOI.
  • Radke PW; Heinl-Green A; Frass OM; Griesenbach U; Ferrari S; Geddes DM; Alton EW. (Aug 2004). Effects of intramyocardial pVEGF165 delivery on regional myocardial blood flow: evidence for a spatial 'delivery-efficacy' mismatch. Gene Ther. 11:1249-1255. DOI.
  • Munkonge F; Alton EW; Andersson C; Davidson H; Dragomir A; Edelman A; Farley R; Hjelte L; et alMcLachlan G; Stern M; Roomans GM. (Aug 2004). Measurement of halide efflux from cultured and primary airway epithelial cells using fluorescence indicators. J Cyst Fibros. 3 Suppl 2:171-176. DOI.
  • Degabriele NM; Griesenbach U; Sato K; Post MJ; Zhu J; Williams J; Jeffery PK; Geddes DM; et alAlton EW. (Jul 2004). Critical appraisal of the mouse model of myocardial infarction. Exp Physiol. 89:497-505. DOI.
  • McShane D; Davies JC; Wodehouse T; Bush A; Geddes D; Alton EW. (Jul 2004). Normal nasal mucociliary clearance in CF children: evidence against a CFTR-related defect. Eur Respir J. 24:95-100.
  • Alton EW; United Kingdom Cystic Fibrosis Gene Therapy Consortium. (2004). Use of nonviral vectors for cystic fibrosis gene therapy. Proc Am Thorac Soc. 1:296-301. DOI.
  • Griesenbach U; Geddes DM; Alton EW. (Oct 2003). Update on gene therapy for cystic fibrosis. Curr Opin Mol Ther. 5:489-494.
  • Stern M; Ulrich K; Geddes DM; Alton EW. (Aug 2003). Poly (D, L-lactide-co-glycolide)/DNA microspheres to facilitate prolonged transgene expression in airway epithelium in vitro, ex vivo and in vivo. Gene Ther. 10:1282-1288. DOI.
  • Munkonge FM; Dean DA; Hillery E; Griesenbach U; Alton EW. (16 Jun 2003). Emerging significance of plasmid DNA nuclear import in gene therapy. Adv Drug Deliv Rev. 55:749-760.
  • McShane D; Davies JC; Davies MG; Bush A; Geddes DM; Alton EW. (Jan 2003). Airway surface pH in subjects with cystic fibrosis. Eur Respir J. 21:37-42.
  • Ferrari S; Geddes DM; Alton EW. (5 Dec 2002). Barriers to and new approaches for gene therapy and gene delivery in cystic fibrosis. Adv Drug Deliv Rev. 54:1373-1393.
  • Davies JC; Potter M; Bush A; Rosenthal M; Geddes DM; Alton EW. (Oct 2002). Bone marrow stem cells do not repopulate the healthy upper respiratory tract. Pediatr Pulmonol. 34:251-256. DOI.
  • Griesenbach U; Ferrari S; Geddes DM; Alton EW. (Oct 2002). Gene therapy progress and prospects: cystic fibrosis. Gene Ther. 9:1344-1350. DOI.
  • Griesenbach U; Cassady RL; Cain RJ; duBois RM; Geddes DM; Alton EW. (Aug 2002). Cytoplasmic deposition of NFkappaB decoy oligonucleotides is insufficient to inhibit bleomycin-induced pulmonary inflammation. Gene Ther. 9:1109-1115. DOI.
  • Oceandy D; McMorran BJ; Smith SN; Schreiber R; Kunzelmann K; Alton EW; Hume DA; Wainwright BJ. (1 May 2002). Gene complementation of airway epithelium in the cystic fibrosis mouse is necessary and sufficient to correct the pathogen clearance and inflammatory abnormalities. Hum Mol Genet. 11:1059-1067.
  • Griesenbach U; Cassady RL; Ferrari S; Fukumura M; Müller C; Schmitt E; Zhu J; Jeffery PK; et alNagai Y; Geddes DM; Hasegawa M; Alton EW. (Feb 2002). The nasal epithelium as a factory for systemic protein delivery. Mol Ther. 5:98-103. DOI.
  • Dickinson P; Smith SN; Webb S; Kilanowski FM; Campbell IJ; Taylor MS; Porteous DJ; Willemsen R; et alde Jonge HR; Farley R; Alton EW; Dorin JR. (1 Feb 2002). The severe G480C cystic fibrosis mutation, when replicated in the mouse, demonstrates mistrafficking, normal survival and organ-specific bioelectrics. Hum Mol Genet. 11:243-251.
  • Davies JC; Geddes DM; Alton EW. (Sep 2001). Gene therapy for cystic fibrosis. J Gene Med. 3:409-417. DOI.
  • Ferrari S; Kitson C; Farley R; Steel R; Marriott C; Parkins DA; Scarpa M; Wainwright B; et alEvans MJ; Colledge WH; Geddes DM; Alton EW. (Sep 2001). Mucus altering agents as adjuncts for nonviral gene transfer to airway epithelium. Gene Ther. 8:1380-1386. DOI.
  • Griesenbach U; Alton EW. (Aug 2001). Recent progress in gene therapy for cystic fibrosis. Curr Opin Mol Ther. 3:385-389.
  • Davies JC; Geddes DM; Alton EW. (Jun 2001). Prospects for gene therapy in lung disease. Curr Opin Pharmacol. 1:272-277.
  • Scheid P; Kempster L; Griesenbach U; Davies JC; Dewar A; Weber PP; Colledge WH; Evans MJ; et alGeddes DM; Alton EW. (Jan 2001). Inflammation in cystic fibrosis airways: relationship to increased bacterial adherence. Eur Respir J. 17:27-35.
  • Yonemitsu Y; Kitson C; Ferrari S; Farley R; Griesenbach U; Judd D; Steel R; Scheid P; et alZhu J; Jeffery PK; Kato A; Hasan MK; Nagai Y; Masaki I; Fukumura M; Hasegawa M; Geddes DM; Alton EW. (Sep 2000). Efficient gene transfer to airway epithelium using recombinant Sendai virus. Nat Biotechnol. 18:970-973. DOI.
  • Griesenbach U; Scheid P; Hillery E; de Martin R; Huang L; Geddes DM; Alton EW. (Feb 2000). Anti-inflammatory gene therapy directed at the airway epithelium. Gene Ther. 7:306-313. DOI.
  • Jaffé A; Judd D; Ratcliffe C; Cheng SH; Bush A; Geddes DM; Alton EW. (Feb 2000). Cationic lipid-mediated gene transfer to the growing murine and human airway. Gene Ther. 7:273-278. DOI.
  • Lukacs KV; Pardo OE; Colston MJ; Geddes DM; Alton EW. (2000). Heat shock proteins in cancer therapy. Adv Exp Med Biol. 465:363-368.
  • Stern M; Geddes DM; Alton EW. (2000). Taking stock of gene therapy for cystic fibrosis. Respir Res. 1:78-81.
  • Lukacs KV; Porter CD; Pardo OE; Oakley RE; Steel RM; Judd DV; Browning JE; Geddes DM; et alAlton EW. (20 Sep 1999). In vivo transfer of bacterial marker genes results in differing levels of gene expression and tumor progression in immunocompetent and immunodeficient mice. Hum Gene Ther. 10:2373-2379. DOI.
  • Griesenbach U; Geddes DM; Alton EW. (Aug 1999). The pathogenic consequences of a single mutated CFTR gene. Thorax. 54 Suppl 2:S19-S23.
  • Kitson C; Angel B; Judd D; Rothery S; Severs NJ; Dewar A; Huang L; Wadsworth SC; et alCheng SH; Geddes DM; Alton EW. (Apr 1999). The extra- and intracellular barriers to lipid and adenovirus-mediated pulmonary gene transfer in native sheep airway epithelium. Gene Ther. 6:534-546. DOI.
  • Alton EW; Stern M; Farley R; Jaffe A; Chadwick SL; Phillips J; Davies J; Smith SN; et alBrowning J; Davies MG; Hodson ME; Durham SR; Li D; Jeffery PK; Scallan M; Balfour R; Eastman SJ; Cheng SH; Smith AE; Meeker D; Geddes DM. (20 Mar 1999). Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: a double-blind placebo-controlled trial. Lancet. 353:947-954.
  • Jaffé A; Bush A; Geddes DM; Alton EW. (Mar 1999). Prospects for gene therapy in cystic fibrosis. Arch Dis Child. 80:286-289.
  • Davies J; Dewar A; Bush A; Pitt T; Gruenert D; Geddes DM; Alton EW. (Mar 1999). Reduction in the adherence of Pseudomonas aeruginosa to native cystic fibrosis epithelium with anti-asialoGM1 antibody and neuraminidase inhibition. Eur Respir J. 13:565-570.
  • Alton EW; Griesenbach U; Geddes DM. (Feb 1999). Gene therapy for asthma: inspired research or unnecessary effort?. Gene Ther. 6:155-156. DOI.
  • Smith SN; Middleton PG; Chadwick S; Jaffe A; Bush KA; Rolleston S; Farley R; Delaney SJ; et alWainwright B; Geddes DM; Alton EW. (Jan 1999). The in vivo effects of milrinone on the airways of cystic fibrosis mice and human subjects. Am J Respir Cell Mol Biol. 20:129-134.
  • Davies JC; Geddes DM; Alton EW. (Jul 1998). Prospects for gene therapy for cystic fibrosis. Mol Med Today. 4:292-299.
  • Yonemitsu Y; Alton EW; Komori K; Yoshizumi T; Sugimachi K; Kaneda Y. (Jun 1998). HVJ (Sendai virus) liposome-mediated gene transfer: current status and future perspectives (review). Int J Oncol. 12:1277-1285.
  • Stern M; Sorgi F; Hughes C; Caplen NJ; Browning JE; Middleton PG; Gruenert DC; Farr SJ; et alHuang L; Geddes DM; Alton EW. (May 1998). The effects of jet nebulisation on cationic liposome-mediated gene transfer in vitro. Gene Ther. 5:583-593. DOI.
  • Smith SN; Delaney SJ; Dorin JR; Farley R; Geddes DM; Porteous DJ; Wainwright BJ; Alton EW. (Feb 1998). Effect of IBMX and alkaline phosphatase inhibitors on Cl- secretion in G551D cystic fibrosis mutant mice. Am J Physiol. 274:C492-C499.
  • Stern M; Caplen NJ; Browning JE; Griesenbach U; Sorgi F; Huang L; Gruenert DC; Marriot C; et alCrystal RG; Geddes DM; Alton EW. (Jan 1998). The effect of mucolytic agents on gene transfer across a CF sputum barrier in vitro. Gene Ther. 5:91-98. DOI.
  • Chadwick SL; Kingston HD; Stern M; Cook RM; O'Connor BJ; Lukasson M; Balfour RP; Rosenberg M; et alCheng SH; Smith AE; Meeker DP; Geddes DM; Alton EW. (Sep 1997). Safety of a single aerosol administration of escalating doses of the cationic lipid GL-67/DOPE/DMPE-PEG5000 formulation to the lungs of normal volunteers. Gene Ther. 4:937-942. DOI.
  • Alton EW; Geddes DM. (18 Jun 1997). Prospects for respiratory gene therapy. Br J Hosp Med. 58:47-49.
  • Davies JC; Stern M; Dewar A; Caplen NJ; Munkonge FM; Pitt T; Sorgi F; Huang L; et alBush A; Geddes DM; Alton EW. (Jun 1997). CFTR gene transfer reduces the binding of Pseudomonas aeruginosa to cystic fibrosis respiratory epithelium. Am J Respir Cell Mol Biol. 16:657-663.
  • Li D; Wang D; Majumdar S; Jany B; Durham SR; Cottrell J; Caplen N; Geddes DM; et alAlton EW; Jeffery PK. (Mar 1997). Localization and up-regulation of mucin (MUC2) gene expression in human nasal biopsies of patients with cystic fibrosis. J Pathol. 181:305-310. DOI.
  • Alton EW; Norris AA. (Nov 1996). Chloride transport and the actions of nedocromil sodium and cromolyn sodium in asthma. J Allergy Clin Immunol. 98:S102-S105.
  • Alton EW. (Aug 1996). A mild variant of cystic fibrosis. Thorax. 51 Suppl 2:S51-S54.
  • Middleton PG; Geddes DM; Alton EW. (Jul 1996). Trimethoprim and tetracycline inhibit airway epithelial sodium absorption. Am J Respir Crit Care Med. 154:18-23.
  • Alton EW; Kingsleigh-Smith DJ; Munkonge FM; Smith SN; Lindsay AR; Gruenert DC; Jeffery PK; Norris A; et alGeddes DM; Williams AJ. (Apr 1996). Asthma prophylaxis agents alter the function of an airway epithelial chloride channel. Am J Respir Cell Mol Biol. 14:380-387.
  • Stern M; Munkonge FM; Caplen NJ; Sorgi F; Huang L; Geddes DM; Alton EW. (Dec 1995). Quantitative fluorescence measurements of chloride secretion in native airway epithelium from CF and non-CF subjects. Gene Ther. 2:766-774.
  • Caplen NJ; Kinrade E; Sorgi F; Gao X; Gruenert D; Geddes D; Coutelle C; Huang L; et alAlton EW; Williamson R. (Nov 1995). In vitro liposome-mediated DNA transfection of epithelial cell lines using the cationic liposome DC-Chol/DOPE. Gene Ther. 2:603-613.
  • Hart SL; Mayall E; Stern M; Munkonge FM; Frost A; Huang L; Vasilliou M; Williamson R; et alAlton EW; Coutelle C. (Sep 1995). The introduction of two silent mutations into a CFTR cDNA construct allows improved detection of exogenous mRNA in gene transfer experiments. Hum Mol Genet. 4:1597-1602.
  • Geddes DM; Alton EW. (Jun 1995). Gene therapy for cystic fibrosis. Neth J Med. 46:306-313.
  • Alton EW; Geddes DM. (Mar 1995). Gene therapy for cystic fibrosis: a clinical perspective. Gene Ther. 2:88-95.
  • Smith SN; Steel DM; Middleton PG; Munkonge FM; Geddes DM; Caplen NJ; Porteous DJ; Dorin JR; et alAlton EW. (Feb 1995). Bioelectric characteristics of exon 10 insertional cystic fibrosis mouse: comparison with humans. Am J Physiol. 268:C297-C307.
  • Alton EW. (1995). Gene therapy for cystic fibrosis. J Inherit Metab Dis. 18:501-507.
  • Caplen NJ; Alton EW; Middleton PG; Dorin JR; Stevenson BJ; Gao X; Durham SR; Jeffery PK; et alHodson ME; Coutelle C. (Jan 1995). Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Nat Med. 1:39-46.
  • Munkonge FM; Osborne LR; Geddes DM; Alton EW. (30 Dec 1994). Lack of inhibition by dideoxy-forskolin and verapamil of DIDS-sensitive volume-activated Cl- secretion in human squamous lung carcinoma epithelial cells. Biochim Biophys Acta. 1224:342-348.
  • Middleton PG; Geddes DM; Alton EW. (Nov 1994). Protocols for in vivo measurement of the ion transport defects in cystic fibrosis nasal epithelium. Eur Respir J. 7:2050-2056.
  • Middleton PG; Caplen NJ; Gao X; Huang L; Gaya H; Geddes DM; Alton EW. (Mar 1994). Nasal application of the cationic liposome DC-Chol:DOPE does not alter ion transport, lung function or bacterial growth. Eur Respir J. 7:442-445.
  • Steel DM; Graham A; Geddes DM; Alton EW. (Jan 1994). Characterization and comparison of ion transport across sheep and human airway epithelium. Epithelial Cell Biol. 3:24-31.
  • Tsang VT; Alton EW; Hodson ME; Yacoub M. (Oct 1993). In vitro bioelectric properties of bronchial epithelium from transplanted lungs in recipients with cystic fibrosis. Thorax. 48:1006-1011.
  • Osborne LR; Lynch M; Middleton PG; Alton EW; Geddes DM; Pryor JP; Hodson ME; Santis GK. (Oct 1993). Nasal epithelial ion transport and genetic analysis of infertile men with congenital bilateral absence of the vas deferens. Hum Mol Genet. 2:1605-1609.
  • Graham A; Hasani A; Alton EW; Martin GP; Marriott C; Hodson ME; Clarke SW; Geddes DM. (Oct 1993). No added benefit from nebulized amiloride in patients with cystic fibrosis. Eur Respir J. 6:1243-1248.
  • Alton EW; Middleton PG; Caplen NJ; Smith SN; Steel DM; Munkonge FM; Jeffery PK; Geddes DM; et alHart SL; Williamson R. (Oct 1993). Non-invasive liposome-mediated gene delivery can correct the ion transport defect in cystic fibrosis mutant mice. Nat Genet. 5:135-142. DOI.
  • Middleton PG; Geddes DM; Alton EW. (Aug 1993). Effect of amiloride and saline on nasal mucociliary clearance and potential difference in cystic fibrosis and normal subjects. Thorax. 48:812-816.
  • Graham A; Steel DM; Wilson R; Cole PJ; Alton EW; Geddes DM. (Jan 1993). Effects of purified Pseudomonas rhamnolipids on bioelectric properties of sheep tracheal epithelium. Exp Lung Res. 19:77-89.
  • Rogers DF; Alton EW; Dewar A; Lethem MI; Barnes PJ. (Jan 1993). Impaired stimulus-evoked mucus secretion in cystic fibrosis bronchi. Exp Lung Res. 19:37-53.
  • Alton EW; Rogers DF; Logan-Sinclair R; Yacoub M; Barnes PJ; Geddes DM. (Dec 1992). Bioelectric properties of cystic fibrosis airways obtained at heart-lung transplantation. Thorax. 47:1010-1014.
  • Graham A; Alton EW; Geddes DM. (Sep 1992). Effects of 5-hydroxytryptamine and 5-hydroxytryptamine receptor agonists on ion transport across mammalian airway epithelia. Clin Sci (Lond). 83:331-336.
  • Smith SN; Alton EW; Geddes DM. (Jun 1992). Ion transport characteristics of the murine trachea and caecum. Clin Sci (Lond). 82:667-672.
  • Alton EW; Williams AJ. (Jun 1992). Modification of gating of an airway epithelial chloride channel by 5-nitro-2-(3-phenylpropylamino)benzoic acid (NPPB). J Membr Biol. 128:141-151.
  • Madden BP; Hodson ME; Yacoub MH; Alton EW; Barnes PJ; Denison DM; Kay AB; Newman-Taylor A; et alGeddes DM. (28 Mar 1992). Heart-lung transplantation for cystic fibrosis. BMJ. 304:835-836.
  • Graham A; Steel DM; Alton EW; Geddes DM. (1992). Second-messenger regulation of sodium transport in mammalian airway epithelia. J Physiol. 453:475-491.
  • Alton EW; Manning SD; Schlatter PJ; Geddes DM; Williams AJ. (Nov 1991). Characterization of a Ca(2+)-dependent anion channel from sheep tracheal epithelium incorporated into planar bilayers. J Physiol. 443:137-159.
  • Alton EW; Khagani A; Taylor RF; Logan-Sinclair R; Yacoub M; Geddes DM. (Jan 1991). Effect of heart-lung transplantation on airway potential difference in patients with and without cystic fibrosis. Eur Respir J. 4:5-9.
  • Nichol GM; Alton EW; Nix A; Geddes DM; Chung KF; Barnes PJ. (Sep 1990). Effect of inhaled furosemide on metabisulfite- and methacholine-induced bronchoconstriction and nasal potential difference in asthmatic subjects. Am Rev Respir Dis. 142:576-580.
  • Alton EW; Currie D; Logan-Sinclair R; Warner JO; Hodson ME; Geddes DM. (Sep 1990). Nasal potential difference: a clinical diagnostic test for cystic fibrosis. Eur Respir J. 3:922-926.

Chapters in books

  • Davies JC; Alton EWFW. Non-viral vectors for gene therapy. In Airway gene therapy. 2, 2:291-314. Huang L (ed); Hung MC (ed); Wagner E (ed). (2005).
  • Griesenbach U; Geddes DM; Alton EW. Genetics and pathogenesis of cystic fibrosis. In Textbook of respiratory cell and molecular biology. 403-418. (2002).

Conferences

  • Alton E. Measures of CFTR molecular and clinical function. 178-179. (2007).
  • Mitomo K; Inoue M; Iwasaki H; Tabata TA; Yoshizaki M; Nagashima N; Washizawa KT; Fujikawa S; et alAkiba E; Geddes DM; Griesenbach U; Alton EWFW; Hasegawa M. Detection of clustered GFP positive cells transduced by lentiviral vector pseudotyped sendai virus envelopes in mouse nasal epithelium. 10:445-445. (Apr 2008).
  • Larsen MDB; Griesenbach U; Goussard S; Geddes DM; Grillot-Courvalin C; Alton EWFW. Bactofection into airway epithelial cells in vitro and in vivo using a genetically modified Escherichia coli. 62:A105-A105. (Dec 2007).
  • Xenariou S; Griesenbach U; Liang HD; Zhu J; Farley R; Somerton L; Singh C; Jeffery PK; et alBlomley M; Alton E. Assessing ultrasound as a method to enhance non-viral gene transfer to the lung. Winter Meeting of the British-Thoracic-Society. 62:A105-A105. (Dec 2007).
  • Horsley AR; Aziz Z; Macleod KA; Saunders CJ; Meister M; Tyler P; Dewar M; Gray R; et alVoase N; Cunningham S; Greening AP; Davies JC; Alton E; Hansell D; Innes JA. Functional and structural changes in the cystic fibrosis lung following antibiotic treatment for exacerbation. Winter Meeting of the British-Thoracic-Society. 62:A31-A31. (Dec 2007).
  • Aziz ZA; Wells A; Meister M; Tyler P; Davies J; Alton E; Innes A; Gray R; et alHorsley A; Hansell D. Computed tomography in infective exacerbations in cystic fibrosis: Serial change and observer agreement. Winter Meeting of the British-Thoracic-Society. 62:A30-A31. (Dec 2007).
  • Davies JC; Voase N; Dewar M; Mullard K; Gammie F; Saunders C; Horsley A; Gray R; et alMacleod K; Somerton L; Higgins T; Donovan J; Cornish N; Ashby D; Geddes D; Greening A; Cunningham S; Innes A; Alton E. Uk CF gene therapy consortium tracking study: Response of clinically available assays to intravenous antibiotics. 62:A30-A30. (Dec 2007).
  • Griesenbach U; Jeswiet SB; Larsen MDB; Bakar Y; Voase NWG; Gammie FM; Mullard KE; Geddes DM; et alDavies JC; Alton EWFW; Marriott C; Gray R; Horsley A; Imrie M; Dewar M; Greening AP; Innes A. UK cf gene therapy consortium tracking study: Change in sputum properties in response to IV antibiotics. 62:A30-A30. (Dec 2007).
  • Davidson H; Wilson A; Gray RD; Horsley A; Pringle I; McLachlan G; Gibson J; Holder E; et alJones L; Doherty A; Coles R; Sumner-Jones S; Wasowicz M; Manvell M; Griesenbach U; Hyde SC; Gill DR; Davies J; Collie DDS; Alton E; Porteous DJ; Boyd AC. Development of an immunocytochemical assay to detect human CFTR expression following gene therapy. 5th Annual Conference of the British-Society-for-Gene-Therapy. 19:416-416. (Apr 2008).
  • Mitomo K; Griesenbach U; Inoue M; Washizawa K; Fujikawa S; Iwasaki H; Somerton L; Farley R; et alSingh C; Hasegawa M; Alton E. Potential airway stem/progenitor cell integration after transduction with a lentiviral vector pseudotyped with Sendai virus envelope proteins. 5th Annual Conference of the British-Society-for-Gene-Therapy. 19:404-404. (Apr 2008).
  • Griesenbach U; Vicente CC; Green AM; Cheng SH; Scheule RK; Pringle IA; Gill DR; Hyde SC; et alAlton EWFW. Successful transfection of human air liquid interface cultures in vivo with the non-viral gene transfer agent GL67A. 19:1155-1156. (Oct 2008).
  • Larsen MDB; Griesenbach U; Alton EWFW. Tight junction openers increase non-viral gene transfer to the airway epithelium in vivo. 19:1125-1125. (Oct 2008).
  • Davies JC; Alton EWFW. Monitoring Respiratory Disease Severity in Cystic Fibrosis. 54:606-615. (May 2009).
  • Tan H; Regamey N; Hilliard T; Alton E; Bush A; Lloyd CM; Davies JC. EXPLORING THE PHENOTYPE OF THE LYMPHOCYTIC INFILTRATE IN THE CF AIRWAY: DO IL-17+CELLS PLAY A ROLE IN DISEASE PATHOGENESIS?. 64:A110-A111. (Dec 2009). DOI.
  • Voase NWG; Davies G; Reid PA; Macleod KA; Dewar MH; Bell NJ; Saunders C; Greening AP; et alCunningham S; Innes JA; Alton EWFW; Davies JC. SUCCESS AND UTILITY OF SPUTUM INDUCTION IN NON-EXPECTORATING CF SUBJECTS: DATA FROM THE UK CF GENE THERAPY RUN-IN STUDY. 64:A110-A110. (Dec 2009). DOI.
  • Davies JC; Davies G; Voase N; Hyde S; Innes A; Boyd C; Porteous D; Higgins T; et alGriesenbach U; Gill D; Alton EWFW. EVALUATION OF SAFETY AND GENE EXPRESSION WITH A SINGLE DOSE OF PGM169/GL67A ADMINISTERED TO THE NOSE AND LUNG OF INDIVIDUALS WITH CYSTIC FIBROSIS: THE UK CF GENE THERAPY CONSORTIUM "PILOT STUDY''. 64:A70-A70. (Dec 2009). DOI.
  • Griesenbach U; Mitomo K; Inoue M; Somerton L; Meng C; Tabata T; Ueda Y; Frankel G; et alFarley R; Singh C; Chan M; Munkonge F; Brum A; Xenariou S; Escudero-Garcia S; Hasegawa M; Alton EWFW. TOWARDS GENE THERAPY FOR CYSTIC FIBROSIS USING A LENTIVIRUS PSEUDOTYPED WITH SENDAI VIRUS ENVELOPES. 64:A69-A70. (Dec 2009). DOI.
  • Duff R; Simmonds N; Pantelidis P; Wilson R; Davies J; Alton E; Cookson W; Moffat M; et alBilton D. MOLECULAR DETECTION OF COMPLEX MICROBIAL COMMUNITIES IN SPUTA OF PATIENTS WITH CYSTIC FIBROSIS AND NON-CF BRONCHIECTASIS. 64:A63-A63. (Dec 2009). DOI.
  • Pringle IA; Hewitt AM; Connolly M; Lawton AE; Voase NWG; Larsen M; Manvelle M; Donovan J; et alMohamedhossen MH; Davies J; Alton EWFW; McLachlan G; Collie DD; Hyde SC; Gill DR. Exploiting Single-Cell-PCR Technology To Determine the Percentage of Transfected Cells in the Respiratory Epithelium. 17:S125-S125. (May 2009).
  • Griesenbach U; Roberts MJ; Vicente CC; Cheng S; Scheule R; Pringle IA; Green AM; Lawton AE; et alPlant KE; Hyde SC; Gill DR; Vrettou C; Baker A; Tennant P; McLachlan G; Collie DDS; Alton EWFW. Secreted Gaussia Luciferase Is a More Sensitive Reporter Than Firefly Luciferase for Non-Viral Gene Transfer to Airway Epithelium Ex Vivo and In Vivo. 17:S123-S124. (May 2009).
  • Nunez-Alonso GA; Davies LA; Bazzani RP; Cornish N; Zhu J; Alton EWFW; Hyde SC; Gill DR. Repeated Exposure to pDNA/PEI Aerosols Results in Minimal Detectable Toxicity in the Mouse Lungs. 17:S123-S123. (May 2009).
  • Saunders CJ; Davies G; Bell NJ; Reid PA; Sheridan HS; Hyde C; Innes JA; Alton EWFW. EXERCISE CAPACITY AND PHYSICAL ACTIVITY IN PATIENTS WITH CF: DATA FROM THE UK CF GENE THERAPY CONSORTIUM (UKCFGTC) 'RUN-IN' STUDY. 65:A123-A124. (Dec 2010). DOI.
  • Davies JC; Conway JH; Fleming J; Dewar M; Voase N; Alton EWFW; Greening A; Hansell D; et alInnes JA. PULMONARY IMAGING TECHNIQUES TO IDENTIFY SUITABLE PATIENTS AND ACT AS OUTCOME MEASURES IN THE UK CF GENE THERAPY CONSORTIUM CLINICAL PROGRAMME. 65:A123-A123. (Dec 2010). DOI.
  • Innes JA; Donovan J; Soussi S; Newman N; Leiton J; Campbell K; Gibson J; Doherty A; et alAlton EWFW; Boyd C; Griesenbach U; Davies JC. INFLAMMATORY MARKERS: DATA FROM THE UK CF GENE THERAPY CONSORTIUM RUN-IN STUDY. 65:A122-A123. (Dec 2010). DOI.
  • Kernan NG; Cullinan P; Alton EWFW; Bilton D; Griesenbach U. ORAL CONTRACEPTIVE USE DOES NOT AFFECT CF DISEASE SEVERITY. 65:A121-A121. (Dec 2010). DOI.
  • Singh C; Munkonge FM; Smith SN; Griesenbach U; Carzaniga R; Tillmann P; Cheng S; Rogers A; et alDewar A; Alton EWFW. QUANTITATIVE BIOLOGICAL IMAGING OF PLASMID DNA IN LIVE HUMAN AIRWAY EPITHELIAL CELLS FOLLOWING NON-VIRAL GENE TRANSFER. 65:A121-A121. (Dec 2010). DOI.
  • Naderi K; Donovan J; Brown S; Leaver N; Tan HL; Alton EWFW; Bush A; Davies JC. REDUCED AIRWAY BETA-DEFENSIN 2 LEVELS IN CHILDREN WITH CYSTIC FIBROSIS AND VITAMIN D-DEFICIENCY. 65:A107-A107. (Dec 2010). DOI.
  • Alton EWFW; Boyd C; Cunningham S; Davies JC; Hyde SC; Ianes JA; Gill DR; Greening A; et alGriesenbach U; Higgins T; Porteous DJ. LONGITUDINAL ASSESSMENT OF BIOMARKERS FOR CLINICAL TRIALS OF NOVEL THERAPEUTIC AGENTS: THE RUN-IN STUDY. 65:A11-A11. (Dec 2010). DOI.
  • Sheridan HS; Bell NJ; Macleod KA; Reid PA; Horsley AR; Davies G; Saunders C; Cunningham S; et alInnes JA; Davies JC; Alton EW. LUNG CLEARANCE INDEX, FEV1 AND CT FINDINGS IN CYSTIC FIBROSIS: DATA FROM THE UK CF GENE THERAPY CONSORTIUM RUN-IN STUDY. 65:A13-A13. (Dec 2010). DOI.
  • Griesenbach U; Vicente CC; Green AM; Cheng SH; Pringle IA; Hyde SC; Gill DR; McLachlan G; et alCollie D; Alton EW. Secreted gaussia luciferase is a sensitive reporter of gene transfer in the sheep lung. 19:1123-1123. (Oct 2008).
  • Shirohzu H; Mitomo K; Tabata T; Griesenbach U; Hyde SC; Alton EW; Ueda Y; Hasegawa M. Efficient in vivo transduction of mouse airway epithelial cells by the Simian immunodeficiency virus vector pseudotyped with Sendai virus F and HN proteins. 7th Annual Meeting of the American-Society-of-Gene-Therapy. 9:S188-S188. (May 2004).
  • Radke PW; Heinl-Green A; Frass OM; Post M; Geddes DM; Alton EW. Evaluation of the porcine ameroid constrictor model of chronic myocardial ischemia for therapeutic angiogenesis studies. 41:331A-331A. (19 Mar 2003).
  • Radke PW; Kivela A; Vick T; Griesenbach U; Yla-Hertualla S; Alton EW. Efficacy of vascular oligonucleotide transfer using polymer-coated stents. 94:27E-28E. (30 Sep 2004).
  • Griesenbach U; Darlay R; Marshall N; Dean P; Williams J; Zhu J; Jeffery P; Gill D; et alGeddes DM; Alton EW. Optimisation of adenoviral and plasmid-mediated gene transfer to the murine myocardium. 6:S22-S22. (Sep 2004).
Share this on DeliciousTweet thisDigg thisStumble thisShare this on Facebook